At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 78 enrolled
Drug / intervention
Crystalens AO +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Three Arm Prospective Clinical Evaluation of Three FDA Approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction.
In Brief
A Phase 4 clinical trial evaluating Crystalens AO, ReSTOR, and 1 other intervention for Cataract. Completed, enrolled 78 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the efficacy and subject satisfaction with three different FDA approved lenses for adults over 40 years of age who desire a reduction in spectacle dependence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionJun 2012
Study CompletionSep 2012
TodayJul 2026
First PostedMay 13, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.1 years ago
Interventions
Crystalens AOdevice
Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
ReSTORdevice
ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
Tecnis Multifocal IOLdevice
Tecnis surgically implanted bilaterally. Study observation up to 180 days.